S&P 500   3,243.63 (-1.57%)
DOW   28,535.80 (-1.57%)
QQQ   218.10 (-2.07%)
AAPL   308.95 (-2.94%)
FB   214.87 (-1.41%)
MSFT   162.28 (-1.67%)
GOOGL   1,431.73 (-2.35%)
AMZN   1,828.34 (-1.79%)
CGC   21.56 (-4.81%)
NVDA   240.20 (-4.10%)
BABA   205.47 (-3.87%)
MU   55.41 (-4.07%)
GE   11.44 (-2.31%)
TSLA   558.02 (-1.20%)
AMD   49.26 (-2.16%)
T   38.25 (-0.65%)
ACB   1.89 (-5.03%)
F   8.89 (-1.22%)
NFLX   342.88 (-2.91%)
PRI   119.08 (-2.82%)
BAC   32.85 (-2.06%)
DIS   135.90 (-2.98%)
GILD   63.83 (+1.08%)
S&P 500   3,243.63 (-1.57%)
DOW   28,535.80 (-1.57%)
QQQ   218.10 (-2.07%)
AAPL   308.95 (-2.94%)
FB   214.87 (-1.41%)
MSFT   162.28 (-1.67%)
GOOGL   1,431.73 (-2.35%)
AMZN   1,828.34 (-1.79%)
CGC   21.56 (-4.81%)
NVDA   240.20 (-4.10%)
BABA   205.47 (-3.87%)
MU   55.41 (-4.07%)
GE   11.44 (-2.31%)
TSLA   558.02 (-1.20%)
AMD   49.26 (-2.16%)
T   38.25 (-0.65%)
ACB   1.89 (-5.03%)
F   8.89 (-1.22%)
NFLX   342.88 (-2.91%)
PRI   119.08 (-2.82%)
BAC   32.85 (-2.06%)
DIS   135.90 (-2.98%)
GILD   63.83 (+1.08%)
S&P 500   3,243.63 (-1.57%)
DOW   28,535.80 (-1.57%)
QQQ   218.10 (-2.07%)
AAPL   308.95 (-2.94%)
FB   214.87 (-1.41%)
MSFT   162.28 (-1.67%)
GOOGL   1,431.73 (-2.35%)
AMZN   1,828.34 (-1.79%)
CGC   21.56 (-4.81%)
NVDA   240.20 (-4.10%)
BABA   205.47 (-3.87%)
MU   55.41 (-4.07%)
GE   11.44 (-2.31%)
TSLA   558.02 (-1.20%)
AMD   49.26 (-2.16%)
T   38.25 (-0.65%)
ACB   1.89 (-5.03%)
F   8.89 (-1.22%)
NFLX   342.88 (-2.91%)
PRI   119.08 (-2.82%)
BAC   32.85 (-2.06%)
DIS   135.90 (-2.98%)
GILD   63.83 (+1.08%)
S&P 500   3,243.63 (-1.57%)
DOW   28,535.80 (-1.57%)
QQQ   218.10 (-2.07%)
AAPL   308.95 (-2.94%)
FB   214.87 (-1.41%)
MSFT   162.28 (-1.67%)
GOOGL   1,431.73 (-2.35%)
AMZN   1,828.34 (-1.79%)
CGC   21.56 (-4.81%)
NVDA   240.20 (-4.10%)
BABA   205.47 (-3.87%)
MU   55.41 (-4.07%)
GE   11.44 (-2.31%)
TSLA   558.02 (-1.20%)
AMD   49.26 (-2.16%)
T   38.25 (-0.65%)
ACB   1.89 (-5.03%)
F   8.89 (-1.22%)
NFLX   342.88 (-2.91%)
PRI   119.08 (-2.82%)
BAC   32.85 (-2.06%)
DIS   135.90 (-2.98%)
GILD   63.83 (+1.08%)
Log in

OTCMKTS:UCBJF - UCB Stock Price, Forecast & News

$86.85
0.00 (0.00 %)
(As of 01/27/2020 04:00 PM ET)
Today's Range
$86.85
Now: $86.85
$86.85
50-Day Range
$79.60
MA: $82.42
$86.85
52-Week Range
$68.95
Now: $86.85
$88.67
VolumeN/A
Average Volume2,568 shs
Market Capitalization$16.89 billion
P/E RatioN/A
Dividend YieldN/A
Beta0.51
UCB SA engages in the research, development, and commercialization of pharmaceutical and biotechnology products. It offers medicinal products such as briviact, keppra, vimpat, neupro, cimzia, nootropil, xyrem, xyzal, and zyrtec. The company was founded by Emmanuel Janssen on January 18, 1928 and is headquartered in Brussels, Belgium.

Industry, Sector and Symbol

Industry Pharmaceutical preparations
Sub-IndustryN/A
SectorMedical
Current SymbolOTCMKTS:UCBJF
CUSIPN/A
CIKN/A
Phone32-2559-9999

Debt

Price-To-Earnings

Sales & Book Value

Annual SalesN/A

Profitability

Miscellaneous

Employees6,828
Market Cap$16.89 billion
Next Earnings DateN/A
OptionableNot Optionable

Receive UCBJF News and Ratings via Email

Sign-up to receive the latest news and ratings for UCBJF and its competitors with MarketBeat's FREE daily newsletter.


UCB (OTCMKTS:UCBJF) Frequently Asked Questions

What is UCB's stock symbol?

UCB trades on the OTCMKTS under the ticker symbol "UCBJF."

What is the consensus analysts' recommendation for UCB?

1 Wall Street analysts have issued "buy," "hold," and "sell" ratings for UCB in the last year. There are currently 1 buy rating for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for UCB.

Has UCB been receiving favorable news coverage?

Headlines about UCBJF stock have trended somewhat negative this week, InfoTrie Sentiment reports. The research group scores the sentiment of news coverage by reviewing more than six thousand blog and news sources in real-time. The firm ranks coverage of companies on a scale of negative five to five, with scores closest to five being the most favorable. UCB earned a coverage optimism score of -1.4 on InfoTrie's scale. They also gave news articles about the company a news buzz of 0.0 out of 10, indicating that recent news coverage is extremely unlikely to have an effect on the stock's share price in the next several days. View News Stories for UCB.

Who are some of UCB's key competitors?

What other stocks do shareholders of UCB own?

Based on aggregate information from My MarketBeat watchlists, some companies that other UCB investors own include Airbus (AIR), UCB S A/ADR (UCBJY), Daimler (DDAIF), Radius Health (RDUS), GW Pharmaceuticals PLC- (GWPH), ABLYNX NV/ADR (ABLX) and Circassia Pharmaceuticals (CIR).

Who are UCB's key executives?

UCB's management team includes the folowing people:
  • Jean-Christophe Tellier, Chief Executive Officer & Executive Director
  • Charl van Zyl, Chief Operating Officer
  • Detlef Thielgen, Chief Financial Officer & Executive Vice President
  • Iris Löw-Friedrich, Chief Medical Officer & Executive Vice President
  • Dhavalkumar Patel, Chief Scientific Officer & EVP

How do I buy shares of UCB?

Shares of UCBJF can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity and Charles Schwab.

What is UCB's stock price today?

One share of UCBJF stock can currently be purchased for approximately $86.85.

How big of a company is UCB?

UCB has a market capitalization of $16.89 billion. UCB employs 6,828 workers across the globe.View Additional Information About UCB.

What is UCB's official website?

The official website for UCB is http://www.ucb.com/.

How can I contact UCB?

UCB's mailing address is 60 ALLEE DE LA RECHERCHE, BRUSSELS C9, 1070. The company can be reached via phone at 32-2559-9999 or via email at [email protected]


MarketBeat Community Rating for UCB (OTCMKTS UCBJF)

Community Ranking:  2.3 out of 5 (star star)
Outperform Votes:  207 (Vote Outperform)
Underperform Votes:  247 (Vote Underperform)
Total Votes:  454
MarketBeat's community ratings are surveys of what our community members think about UCB and other stocks. Vote "Outperform" if you believe UCBJF will outperform the S&P 500 over the long term. Vote "Underperform" if you believe UCBJF will underperform the S&P 500 over the long term. You may vote once every thirty days.
This page was last updated on 1/27/2020 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.

Yahoo Gemini Pixel